Breaking News Instant updates and real-time market news.

AMRN

Amarin

$21.06 /

+1.15 (+5.78%)

, AZN

AstraZeneca

$50.80 /

-0.545 (-1.06%)

08:25
01/22/20
01/22
08:25
01/22/20
08:25

Amarin price target raised to $13 from $8 at Oppenheimer

Oppenheimer analyst Leland Gershell raised his price target for Amarin (AMRN) to $13 from $8 as AstraZeneca (AZN) appears to have no plans to ever launch Epanova. The analyst notes that AstraZeneca has announced plans to close its large CV outcomes trial of Epanova based on a recommendation from the trial's independent data monitoring committee which determined that STRENGTH would be unlikely to demonstrate benefit in the mixed dyslipidemia patient population at increased risk of CV disease. Gershell has an Outperform rating on Amarin's shares.

AMRN

Amarin

$21.06 /

+1.15 (+5.78%)

AZN

AstraZeneca

$50.80 /

-0.545 (-1.06%)

  • 23

    Jan

  • 06

    Feb

  • 13

    Feb

AMRN Amarin
$21.06 /

+1.15 (+5.78%)

01/20/20 Jefferies
Amarin remains in 'good position' in ongoing patent trial, says Jefferies
01/16/20 Jefferies
Amarin in 'good position' as 'heated' patent trial continues, says Jefferies
01/13/20 Roth Capital
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
01/13/20 Stifel
Amarin should rally on failure of two potential competitors, says Stifel
AZN AstraZeneca
$50.80 /

-0.545 (-1.06%)

01/13/20 JPMorgan
Epanova discontinuation positive for Amarin, says JPMorgan
12/26/19 Stifel
Stifel sees path to $230 for Iqvia shares after 'significant' AstraZeneca win

TODAY'S FREE FLY STORIES

Recommendations
Penn National price target raised to $44 from $39 at JPMorgan » 07:58
02/19/20
02/19
07:58
02/19/20
07:58
PENN

Penn National

$36.93 /

+0.07 (+0.19%)

JPMorgan analyst Joseph…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Roper Technologies price target raised to $425 from $400 at Cowen » 07:58
02/19/20
02/19
07:58
02/19/20
07:58
ROP

Roper Technologies

$389.28 /

-3.44 (-0.88%)

Cowen analyst Joseph…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Weichai Power initiated with a Buy at Jefferies » 07:58
02/19/20
02/19
07:58
02/19/20
07:58
WEICY

Weichai Power

$0.00 /

+ (+0.00%)

Jefferies analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Downgrade
NetApp downgraded to Hold at Argus due to slower momentum » 07:57
02/19/20
02/19
07:57
02/19/20
07:57
NTAP

NetApp

$53.44 /

-0.69 (-1.27%)

Argus analyst Jim…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Embraer delivers 198 total jets in 2019 » 07:56
02/19/20
02/19
07:56
02/19/20
07:56
ERJ

Embraer

$17.15 /

-0.29 (-1.66%)

Embraer delivered a total…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Total Access downgraded to Underweight from Overweight at JPMorgan » 07:56
02/19/20
02/19
07:56
02/19/20
07:56
TACYY

Total Access Communications

$0.00 /

+ (+0.00%)

JPMorgan analyst Ranjan …

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Initiation
Collegium Pharmaceutical resumed with a Buy at Jefferies » 07:55
02/19/20
02/19
07:55
02/19/20
07:55
COLL

Collegium Pharmaceutical

$23.11 /

-0.03 (-0.13%)

Jefferies analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
Atlanta Federal Reserve Bank President Raphael Bostic Speech to be released at 08:10  07:55
02/19/20
02/19
07:55
02/19/20
07:55
 
General news
Atlanta Federal Reserve Bank President Raphael Bostic Speech to be released at 08:10  07:55
02/19/20
02/19
07:55
02/19/20
07:55
 
Recommendations
Fluor selloff on SEC investigation an overreaction, says Citi » 07:53
02/19/20
02/19
07:53
02/19/20
07:53
FLR

Fluor

$14.80 /

-4.74 (-24.26%)

Citi analyst Andrew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Walmart analyst day shows encouraging long-term prospects, says Cowen » 07:52
02/19/20
02/19
07:52
02/19/20
07:52
WMT

Walmart

$119.64 /

+1.75 (+1.48%)

Cowen analyst Oliver Chen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
National Oilwell downgraded to Hold at Argus on weaker capital spending » 07:52
02/19/20
02/19
07:52
02/19/20
07:52
NOV

National Oilwell

$22.85 /

-0.04 (-0.17%)

Argus analyst Bill…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Emergent BioSolutions enters into Narcan settlement agreement with Perrigo » 07:50
02/19/20
02/19
07:50
02/19/20
07:50
EBS

Emergent BioSolutions

$63.91 /

+0.68 (+1.08%)

, PRGO

Perrigo

$58.94 /

+1.25 (+2.17%)

, TEVA

Teva

$12.31 /

+0.1 (+0.82%)

In a regulatory filing…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
U.S. mortgage applications dropped -6.4% in the week ended February 14 » 07:50
02/19/20
02/19
07:50
02/19/20
07:50

U.S. mortgage…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
Advanced Energy price target raised to $87 from $78 at Citi » 07:49
02/19/20
02/19
07:49
02/19/20
07:49
AEIS

Advanced Energy

$71.96 /

-4.96 (-6.45%)

Citi analyst Amanda…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Dunkin' Brands downgraded to Hold at Argus on valuation » 07:47
02/19/20
02/19
07:47
02/19/20
07:47
DNKN

Dunkin' Brands

$76.19 /

+0.41 (+0.54%)

Argus analyst John…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Chart Industries price target raised to $86 from $80 at Citi » 07:46
02/19/20
02/19
07:46
02/19/20
07:46
GTLS

Chart Industries

$71.31 /

-2.19 (-2.98%)

Citi analyst J.B. Lowe…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Five Prime downgraded to Neutral at Wedbush as cabiralizumab study flops » 07:45
02/19/20
02/19
07:45
02/19/20
07:45
FPRX

Five Prime

$4.42 /

-0.11 (-2.43%)

, BMY

Bristol-Myers

$66.06 /

-0.32 (-0.48%)

As previously reported,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Westlake Chemical price target lowered to $65 from $74 at Citi » 07:45
02/19/20
02/19
07:45
02/19/20
07:45
WLK

Westlake Chemical

$60.25 /

-4.7 (-7.24%)

Citi analyst P.J. Juvekar…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Manhattan Associates management to meet with Benchmark » 07:44
02/19/20
02/19
07:44
02/19/20
07:44
MANH

Manhattan Associates

$81.18 /

+0.94 (+1.17%)

Group Headquarters…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Everbridge price target raised to $105 from $90 at Canaccord » 07:44
02/19/20
02/19
07:44
02/19/20
07:44
EVBG

Everbridge

$92.00 /

+0.07 (+0.08%)

Canaccord analyst Richard…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Transocean downgraded to Sell from Hold at Argus » 07:43
02/19/20
02/19
07:43
02/19/20
07:43
RIG

Transocean

$4.41 /

-0.12 (-2.65%)

Argus analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Incyte announces results from Phase 3 TRuE-AD program » 07:43
02/19/20
02/19
07:43
02/19/20
07:43
INCY

Incyte

$79.25 /

+0.83 (+1.06%)

Incyte announced that the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Medtronic suffered a 'setback quarter,' says Morgan Stanley » 07:41
02/19/20
02/19
07:41
02/19/20
07:41
MDT

Medtronic

$112.63 /

-4.65 (-3.96%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
InMode price target raised to $48 from $45 at Barclays » 07:40
02/19/20
02/19
07:40
02/19/20
07:40
INMD

InMode

$40.43 /

-3.45 (-7.86%)

Barclays analyst Jack…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.